Patent application number | Description | Published |
20080242742 | Animal models of pancreatic adenocarcinoma and uses therefor - The present invention is based, at least in part, on the generation of an animal model of pancreatic adenocarcinoma which recapitulates the genetic and histological features of human pancreatic adenocarcinoma, including the initiation, maintenance, and progression of the disease. Accordingly, the present invention provides animal models of cancer, e.g., pancreatic adenocarcinoma, wherein an activating mutation of Kras has been introduced, and any one or more known or unknown tumor suppressor genes or loci, e.g., Ink4a/Arf, Ink4a, Arf, p53, Smad4/Dpc, Lkb1, Brca2, or Mlh1, have been misexpressed, e.g., have been misexpressed leading to decreased expression or non-expression. The animal models of the invention may be used, for example, to identify biomarkers of pancreatic cancer, to identify agents for the treatment or prevention of pancreatic cancer, and to evaluate the effectiveness of potential therapeutic agents. | 10-02-2008 |
20090297525 | Compositions, kits and methods for identification, assessment, prevention and therapy of cancer - The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer. | 12-03-2009 |
20090297536 | Compositions, kits, and methods for identification, assessment, prevention and therapy of cancer - The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer. | 12-03-2009 |
20100092476 | PANCREATIC CANCER BIOMARKERS - The present invention provides a method of diagnosing, prognosing or screening for pancreatic cancer in a subject. The method may be carried out on a sample such as a blood or tissue sample collected from the subject. The is carried out by (a) detecting one or more markers in a biological sample of said subject, said markers selected from the markers set forth in Table 1 (e.g. one or more markers selected from the group set forth in Table 2, and/or the group consisting of ALCAM, TIMP-1, ICAM1, LCN2, REG1A, REG3, IGFBP4, TNFRSF1A and WFDC2); and (b) determining an altered level of said marker(s), said altered level indicating said subject may be afflicted with or at risk of developing pancreatic cancer. Kits useful for carrying out the methods are also described. | 04-15-2010 |
20100255004 | RECEPTOR TYROSINE KINASE PROFILING - The invention provides novel methods for designing and administering therapeutic treatments for subjects afflicted with cancer. One aspect provides methods of identifying RTK pathways in a cancer and formulating treatment plans based on a plurality of RTK inhibitors. The invention further provides methods for evaluating candidate tyrosine kinase inhibitors for therapeutic efficacy. | 10-07-2010 |
20100297072 | Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy - A method comprising administering, to a mammal, an oncolytic virus and an immunostimulatory agent. A method of treating a first tumor, a second tumor, or both in a mammal having a first tumor, comprising administering an oncolytic virus into the first tumor; and administering an immunostimulatory agent systemically to the mammal. A kit comprising an oncolytic virus, an immunostimulatory agent, and instructions for administering the oncolytic virus and the immunostimulatory agent to a mammal. A kit comprising an oncolytic virus, an immunostimulatory agent, and instructions for treating a second tumor in a mammal having a first tumor by administering an oncolytic virus into the first tumor; and administering an immunostimulatory agent systemically to the mammal. The methods optionally include administering an additional anticancer therapy. | 11-25-2010 |
20100298158 | Compositions, Kits, and Methods for Identification, Assessment, Prevention, and Therapy of Cancer - The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human cancer. A variety of chromosomal regions (MCRs) and markers corresponding thereto, are provided, wherein alterations in the copy number of one or more of the MCRs and/or alterations in the amount, structure, and/or activity of one or more of the markers is correlated with the presence of cancer. | 11-25-2010 |
20110030074 | COMPOSITIONS AND METHODS FOR CANCER GENE DISCOVERY - The present invention features transgenic non-human mammalian animals being genetically modified to develop cancer. The invention also relates to methods for identifying genes or genetic elements that are potentially related to human cancers using an chromosomally unstable animal model. Information on such genetic alterations can be used to predict cancer therapeutic outcomes and to stratify patient populations to maximize therapeutic efficacy. | 02-03-2011 |
20110172288 | Compositions and Methods for the Identification, Assessment, Prevention and Therapy of Thymic Lymphoma or Hamartomatous Tumours - The subject matter relates to newly discovered nucleic acid molecules and proteins associated with thymic lymphoma and hamartomatous tumors. Compositions and methods for detecting, characterizing, preventing, and treating human thymic lymphoma and hamartomatous tumors are provided. | 07-14-2011 |
20120122991 | METHOD FOR TREATING CANCER BY INCREASING AMP-ACTIVATED KINASE ACTIVITY - The invention relates to modulation of LKB1 or AMP kinase protein activity for treating disorders including diabetes and cancer. The invention also relates to screening for agents that modulate the activity of LKB1 or AMP kinase protein, which are useful in the treatment of diabetes and cancer, as well as preparing compounds for treatment of diabetes and cancer. | 05-17-2012 |